Mainstay treatments are renin-angiotensin-aldosterone system inhibitors, mineralocorticosteroid antagonists and -blockers, and, as mentioned earlier, SGLT-2 inhibitors, especially in people with comorbid diabetes
While generally less bothersome than nausea or vomiting, constipation can persist longer and may require proactive management through increased fiber intake, hydration, and physical activity
Regulatory hesitancy often stems from limited long-term safety data, while consumer acceptance depends not only on scientific assurance but also on transparent communication and regulatory credibility
Trial data have shown decreases in serious cardiovascular complications, including cardiovascular mortality, nonlethal heart attacks, and nonfatal cerebrovascular accidents, among individuals with type 2 diabetes and pre-existing cardiovascular pathology or high cardiovascular risk [3,5,13,14,37]
However, the liquid form may not be readily available in all parts of the world
F., Smith, M., Stolarski, C